Article
Combining molecular testing and the Bethesda category III:VI ratio for thyroid fine-needle aspirates: A quality-assurance metric for evaluating diagnostic performance in a cytopathology laboratory.
Cancer cytopathology - 1 Apr 2022
Gokozan Hamza N, Dilcher Thomas L, Alperstein Susan A, Qiu Yuqing, Mostyka Maria, Scognamiglio Theresa, Solomon James P, Song Wei, Rennert Hanna, Beg Shaham, Stern Evan, Goyal Abha, Siddiqui Momin T, Heymann Jonas J
Abstract excerpt
BACKGROUND: Molecular testing (MT) of thyroid fine-needle aspiration (FNA)-derived genetic material is commonly used to assess malignancy risk for indeterminate cases. The Bethesda System for Reporting Thyroid Cytopathology (TBS) provides limited guidance for the appropriate use of category III (atypia of undetermined significance [AUS]). The authors combined MT with cytomorphology to monitor AUS diagnoses in a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.